Cases & Deals

  • Home
  • Practices
  • Onxeo completes €15 million private placement of new shares

Share

Onxeo completes €15 million private placement of new shares

June 2017

Client(s) Onxeo

Jones Day advised Onxeo, a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology and listed on the regulated markets of Euronext in Paris and Nasdaq OMX in Copenhagen, in connection with its €15 million (US$16.7 million) private placement of new shares to U.S. and European investors.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.